Type 1 diabetes mellitus (T1D) is a chronic disease characterized by an autoimmune
destruction of insulin-producing β-pancreatic cells. Although many advances have been …

For the past century, insulin injections have saved millions of lives, but glycemic instability is
still a persistent challenge for people with diabetes, leading to tremendous morbidity and …

Background Insulin‐secreting cells have been generated from human embryonic or induced
pluripotent stem cells (iPSCs) by mimicking developmental processes. However, these cells …

Abstract Treatment of type 1 diabetes mellitus has always posed a challenge to balance
hyperglycemia control with hypoglycemia episodes. The quest for newer therapies is …

Regenerating human islet organoids from stem cells remains a significant challenge
because of our limited knowledge on cues essential for developing the endocrine organoids …

At the time the first pancreas transplant was performed by Kelly and Lillehei in 1966, insulin
therapy for diabetes was generally available but administered in a form that is known today …

Significant efforts have been invested into the differentiation of stem cells into functional
hepatocyte-like cells that can be used for cell therapy, disease modeling and drug …

The bioartificial pancreas (BAP) represents a viable solution for the treatment of type 1
diabetes (T1D). By encapsulating pancreatic cells in a semipermeable membrane to allow …

Introduction To complement islet transplantation for type1 diabetic patients, cell-based
therapy using pluripotent stem cells such as ES cells and iPS cells is promising. Many …

The production of fully functional insulin-secreting cells to treat diabetes is a major goal of
regenerative medicine. In this article, I review progress towards this goal over the last 15 …